Abstract：
The purpose of this study was to assess changes in time to optimal therapy (TTOT) for bacteremia due to select organisms after implementation of the BioFire® FilmArray® blood culture identification panels at two community teaching hospitals. TTOT (days) was similar in Pre-BCID compared to BCID1 and BCID2 [(2.48 vs. 2.65, p=0.10); (2.48 vs. 2.37, p=0.27)]. There were no significant differences in time to effective antimicrobial therapy between groups. However, there were significantly more therapy changes and appropriate carbapenem use within 24 hours of the Gram stain result for gram-negative organisms in the BCID2 arm compared to the Pre-BCID arm. Additionally, a significant reduction in the duration of vancomycin for gram-positive organisms was noted in the BCID2 arm compared to the Pre-BCID arm. These findings suggest that the incorporation of the BCID2 panel resulted in changes in prescribing practices, leading to more appropriate antimicrobial utilization in a subset of patients.
摘要：
这项研究的目的是评估在两家社区教学医院实施BioFire®FilmArray®血液培养鉴定小组后，由于选择的生物体而导致菌血症的最佳治疗时间（TTOT）的变化。与BCID1和BCID2相比，Pre-BCID的TTOT（天数）相似[（2.48vs.2.65，p=0.10)；(2.48vs.2.37,p=0.27)]。两组之间有效抗菌治疗的时间没有显着差异。然而,与Pre-BCID组相比,BCID2组的革兰氏阴性菌在革兰氏染色结果后24小时内的治疗变化和适当的碳青霉烯使用明显更多.此外,与Pre-BCID组相比,BCID2组的革兰氏阳性菌万古霉素使用时间显著缩短.这些结果表明，BCID2小组的合并导致了处方实践的变化，导致在一部分患者中使用更合适的抗菌药物。
